| Literature DB >> 33936813 |
Tarek Owaidah1, Nouf Al-Numair2, Ayman Al-Suliman2, Mohammed Zolaly3, Rana Hasanato4, Faisal Al Zahrani5, Mohameed Albalawi6, Layla Bashawri5, Khawar Siddiqui7, Faisal Alalaf8, Abdulkareem Almomen4, Muhammad Raihan Sajid9.
Abstract
Iron deficiency is the most prevalent nutritional deficiency worldwide. According to an estimate by the World Health Organization, up to 27% of the world's population experience iron deficiency anemia (IDA). Studies conducted in the Middle East, including Saudi Arabia, have suggested that IDA is the most common cause of anemia, especially among females. This study aimed to determine the prevalence of IDA and iron deficiency (ID) among apparently healthy young university students from four regions in Saudi Arabia. Students were asked to complete a simple survey questionnaire; blood samples were then collected and analyzed after obtaining informed consent. A total of 981 students completed the survey, with 11% of the participants reporting symptoms of anemia; 34% of participants were diagnosed with IDA and 6% reported a diagnosis of hemoglobinopathy. Blood analysis confirmed the prevalence of ID and IDA in 28.6% and 10.7% of the participants, respectively; those with ID and IDA were mostly females (88.5% and 94%, resp.). Thalassemia trait and sickle cell trait were detected in 1.3% and 7% of participants, respectively. Our findings from a national survey among young university in Saudi Arabia indicate a high prevalence of ID and IDA.Entities:
Year: 2020 PMID: 33936813 PMCID: PMC8056870 DOI: 10.1155/2020/6642568
Source DB: PubMed Journal: Anemia ISSN: 2090-1267
Responses to the survey questionnaire (n = 981).
| Inquiry | Female (507) | Male (474) | Total (981) |
|
|---|---|---|---|---|
|
| ||||
| Yes | 73 (14.4%) | 36 (7.6%) | 109 (11.1%) | 0.001 |
| G6PD | 1 (20%) | 4 (80%) | 5 (4.6%) | |
| Iron deficiency/IDA | 33 (89.2%) | 4 (10.8%) | 37 (33.9%) | |
| Anemia | 8 (88.9%) | 1 (11.1%) | 9 (8.3%) | |
| Sickle cell | 2 (50.0%) | 2 (50.0%) | 4 (3.7%) | |
| Sickle cell trait | - | 2 (100%) | 2 (1.8%) | |
| Thalassemia | 1 (100%) | - | 1 (0.9%) | |
| Spherocytosis | 1 (100%) | - | 1 (0.9%) | |
| Type unknown | 27 (54.0%) | 23 (46.0%) | 50 (45.9%) | |
|
| ||||
|
| ||||
| Yes | 49 (9.7%) | 72 (15.2%) | 121 (12.3%) | 0.009 |
|
| ||||
|
| ||||
| Yes | 128 (25.2%) | 171 (36.1%) | 299 (30.5%) | 0.1 |
|
| ||||
|
| ||||
| Yes | 37 (7.3%) | 31 (6.5%) | 68 (6.9%) | 0.706 |
| Hemophilia | 2 (100.0%) | - | 2 (2.9%) | |
| Platelet deficiency | 1 (100.0%) | - | 1 (1.5%) | |
| Don't exactly know the diagnosis | 7 (46.7%) | 8 (53.3%) | 15 (22.1%) | |
Age and hematological profile of the students at the interview.
| Variable |
| Female ( |
| Male ( |
| ||
|---|---|---|---|---|---|---|---|
| Median | (Min–Max) | Median | (Min–Max) | ||||
| Age (years) | 257 | 19.5 | (17.3–25.8) | 301 | 18.9 | (16.3–38.9) | 0.349 |
| Hb (g/dL) | 501 | 12.6 | (6.8–17.0) | 468 | 15.1 | (8.7–17.7) | 0.001 |
| Ferritin (ng/mL) | 502 | 20.5 | (1.6–393.0) | 466 | 90.0 | (4.6–543.0) | 0.001 |
| HCT (%) | 500 | 40.0 | (4.3–56.3) | 468 | 46.0 | (29.8–57.4) | 0.001 |
| MCV (fL) | 501 | 86.0 | (9.4–108.5) | 468 | 85.2 | (10.0–111.8) | 0.555 |
| Plts (109/L) | 490 | 236.0 | (104–592) | 455 | 230.0 | (102–501) | 0.001 |
| MPV (fL) | 499 | 10.0 | (7.1–14.9) | 467 | 9.3 | (6.6–14.2) | 0.001 |
| HbA (%) | 455 | 97.5 | (55.5–98.7) | 401 | 97.3 | (53.9–99.2) | 0.001 |
| HbA2 (%) | 457 | 2.5 | (0.7–5.7) | 402 | 2.6 | (0.8–5.5) | 0.001 |
| HbF (%) | 66 | 0.7 | (0.2–28.9) | 26 | 0.7 | (0.1–7.1) | 0.751 |
| HbS (%) | 25 | 35.6 | (16.6–71.7) | 18 | 34.8 | (16.7–91.3) | 0.941 |
Hb: hemoglobin; Hct: hematocrit; MCV : mean corpuscular volume; Plts: platelets; MPV : mean platelet volume; HbA: hemoglobin A; HbF: fetal hemoglobin; and HbS : an abnormal type of hemoglobin inherited from parents. None of the data conformed to the normality assumption.
Observations based on hematological profile—full Cohort, all regions.
| Observations | Female | Male | Total |
|
|---|---|---|---|---|
|
| ||||
| Group A (ferritin ≥30) | 161 (27.5%) | 424 (72.5%) | 585 (61.2%) | <0.001 |
| Ferritin ≥30, Hb above normal limits | 138 | 416 | ||
| Ferritin ≥30, Hb low | 23 | 8 | ||
| Group B (low ferritin, normal Hb) | 239 (88.8%) | 30 (11.2%) | 269 (28.1%) | |
| Ferritin ≥15 and <30, Hb above normal limits | 136 | 25 | ||
| Ferritin ≥12 and <15, Hb above normal limits | 30 | 3 | ||
| Ferritin <12, Hb above normal limits | 73 | 2 | ||
| Group C (low ferritin and low Hb) | 96 (94.1%) | 6 (5.9%) | 102 (10.7%) | |
| Ferritin ≥15 and <30, Hb low | 20 | 2 | ||
| Ferritin ≥12 and <15, Hb low | 7 | 0 | ||
| Ferritin <12, Hb low | 69 | 4 | ||
|
| ||||
|
| ||||
| Hb-A2 ≤ 3.5% | 450 (98.5%) | 398 (99%) | 848 (98.7%) | |
| Hb-A2 > 3.5% | 7 (1.5%) | 4 (1%) | 11 (1.3%) | |
|
| ||||
|
| ||||
| Hb-S ≤ 23% | 2 (8%) | 1 (5.6%) | 3 (7%) | |
| Hb-S > 23% | 23 (92%) | 17 (94.4%) | 40 (93%) | |
Two students were positive for both thalassemia and sickle cell anemia. ,Male ≥13, female ≥12;male < 13, female <12.
Figure 1Sufficiency profile with respect to ferritin and Hb by gender.
Observations based on the hematological profile (excluding cases of thalassemia and sickle cell disease) by regions with confirmed lab values (n = 908).
| Regions | Group B (low ferritin, normal Hb) | Female | Male | Total |
| Group C (low ferritin and low Hb) | Female | Male | Total |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Dammam | Region total | 34 (81.0%) | 8 (19.0%) | 42/174 (24.1%) | <0.001 | Region total | 17 (85%) | 3 (15%) | 20/174 (11.5%) | 0.001 |
| Ferritin ≥15 and <30, Hb ANL | 19 | 5 | Ferritin ≥15 and <30, Hb low | 4 | 1 | |||||
| Ferritin ≥12 and <15, Hb ANL | 5 | 1 | Ferritin ≥12 and <15, Hb low | 2 | 0 | |||||
| Ferritin <12, Hb ANL | 10 | 2 | Ferritin <12, Hb low | 11 | 2 | |||||
|
| ||||||||||
| Makkah | Region total | 112 (95.7%) | 5 (4.3%) | 117/276 (42.4%) | <0.001 | Region total | 27 (100%) | 0 (0%) | 27/276 (9.8%) | - |
| Ferritin ≥15 and <30, Hb ANL | 58 | 4 | Ferritin ≥15 and <30, Hb low | 5 | 0 | |||||
| Ferritin ≥12 and <15, Hb ANL | 20 | 1 | Ferritin ≥12 and <15, Hb low | 1 | 0 | |||||
| Ferritin <12, Hb ANL | 34 | 0 | Ferritin <12, Hb low | 21 | 0 | |||||
|
| ||||||||||
| Madina | Region total | 47 (81%) | 11 (19.0%) | 58/293 (21%) | <0.001 | Region total | 29 (96.7%) | 1 (3.3%) | 30/293 (10.2%) | 0.033 |
| Ferritin ≥15 and <30, Hb ANL | 29 | 11 | Ferritin ≥15 and <30, Hb low | 4 | 1 | |||||
| Ferritin ≥12 and <15, Hb ANL | 2 | 0 | Ferritin ≥12 and <15, Hb low | 0 | 0 | |||||
| Ferritin <12, Hb ANL | 16 | 0 | Ferritin <12, Hb low | 25 | 0 | |||||
|
| ||||||||||
| Riyadh | Region total | 37 (86.0%) | 6 (14.0%) | 43/165 (26.1%) | <0.001 | Region total | 16 (88.9%) | 2 (11.1%) | 18/165 (10.9%) | 0.007 |
| Ferritin ≥15 and <30, Hb ANL | 22 | 5 | Ferritin ≥15 and <30, Hb low | 5 | 0 | |||||
| Ferritin ≥12 and <15, Hb ANL | 3 | 1 | Ferritin ≥12 and <15, Hb low | 3 | 0 | |||||
| Ferritin <12, Hb ANL | 12 | 0 | Ferritin <12, Hb low | 8 | 2 | |||||
ANL: above normal limits.